News | August 06, 2024
SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs
Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
These gummies are specially formulated for both kids and adults to nourish the eyes and promote optimal vision development
Decision on EU marketing authorisation for this population expected by September 2024
GSK and Flagship to jointly fund up to $150 million upfront
Subscribe To Our Newsletter & Stay Updated
